EP0840591B1 - Systeme pour administration d'unites discretes par voie orale - Google Patents

Systeme pour administration d'unites discretes par voie orale Download PDF

Info

Publication number
EP0840591B1
EP0840591B1 EP96924555A EP96924555A EP0840591B1 EP 0840591 B1 EP0840591 B1 EP 0840591B1 EP 96924555 A EP96924555 A EP 96924555A EP 96924555 A EP96924555 A EP 96924555A EP 0840591 B1 EP0840591 B1 EP 0840591B1
Authority
EP
European Patent Office
Prior art keywords
active agent
chamber
delivery system
agent formulation
discrete units
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP96924555A
Other languages
German (de)
English (en)
Other versions
EP0840591A1 (fr
Inventor
Patrick S.-L. Wong
Howard B. Rosen
Nathan Roth
Phyllis L. Gardner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Priority to EP00200063A priority Critical patent/EP0988850B1/fr
Publication of EP0840591A1 publication Critical patent/EP0840591A1/fr
Application granted granted Critical
Publication of EP0840591B1 publication Critical patent/EP0840591B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A—HUMAN NECESSITIES
    • A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47G—HOUSEHOLD OR TABLE EQUIPMENT
    • A47G21/00—Table-ware
    • A47G21/18—Drinking straws or the like
    • A47G21/183—Drinking straws or the like with means for changing the flavour of the liquid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/0015—Devices specially adapted for taking medicines
    • A61J7/0038—Straws

Definitions

  • the present invention is related to the oral delivery of an active agent. More particularly, a device for oral delivery of an active agent formulation in the form of discrete units mixed with a fluid, by inserting the discrete units into a hollow active agent formulation chamber. A retainer in a first end of the chamber prevents the release of the discrete units from the first end of the chamber while allowing for fluid flow when suction is applied at the second end of the chamber. The discrete units can easily be swallowed in admixture with the fluid drawn through the chamber.
  • Tablets, capsules, caplets and many other types of devices have been used for oral delivery of active agents. These forms are relatively easy to manufacture and convenient for use in the hospital or other institutional settings or at home. Many different types of active agents have been incorporated into such dosage forms - ranging from analgesics to antibiotics to hormones.
  • EP-A-0 383 503 describes a tubular system for delivering a therapeutic agent in free-flowing form to a patient.
  • the therapeutic agent is supported within a tube by a stationary, fluid-permeable grid or within a loop formed in the tube.
  • the therapeutic agent is carried from the stationary gird or the loop by the fluid and dispensed to the patient.
  • an oral active agent delivery system as claimed in claim 1 below.
  • the discrete units contained within the chamber are in particulate form.
  • the discrete units contained within the chamber are in the form of multiple active agent dosage forms.
  • the present invention provides a device for the oral delivery of an active agent formulation in the form of discrete units that is easy to manufacture and use and that can deliver a predetermined amount of active agent.
  • active agent formulation intends the active agent or drug optionally in combination with pharmaceutically acceptable carriers and additional inert ingredients.
  • discrete units intends the active agent formulation in solid or particulate form.
  • oral dosage form as described herein is meant the active agent formulation when placed in a discrete unit that is capable of maintaining its physical configuration and chemical integrity while housed within the delivery device.
  • terapéuticaally effective amount or “therapeutically effective rate” refer to the amount or rate of the active agent needed to effect the desired pharmacologic, often beneficial result.
  • active agent formulation retainer refers to a valve, plug or restriction, or the like that prevents passage of the active agent formulation from the device.
  • fluid passing active agent formulation retainer is intended a valve, plug or restriction or the like that allows for passage of fluids but does not allow for passage of other ingredients such as the active agent formulation that is contained in the delivery device.
  • the dispensing devices of the invention find use where it is inconvenient or unsafe to use solid oral dosage forms such as capsules or tablets.
  • the devices may be particularly useful in geriatric or paediatric patient populations but they may also be useful for those who have difficulty swallowing capsules or tablets.
  • a single delivery device or several devices can be administered to a patient during a therapeutic program.
  • FIG. 1A is a cross-sectional view of one embodiment of the delivery device of the invention in prepared form prior to placement in a liquid medium.
  • FIG. 1B is an enlarged sectional view of the first end of the device of FIG. 1A.
  • FIG. 2A shows the device of FIG.1A following placement in a liquid medium and delivery of a portion of the active agent formulation.
  • FIG. 2B is an enlarged sectional view of the middle section of the device of FIG. 2A.
  • FIG. 3A shows the device of FIG. 1A following complete delivery of the active agent formulation.
  • FIG. 3B is an enlarged sectional view of the second end of the device of FIG. 3A.
  • FIG. 4A is a cross-sectional view
  • FIG. 4B is a bottom view
  • FIGs. 4C and 4D are top views of a second embodiment of the delivery device of the invention in prepared form.
  • FIG. 5 is a cross-sectional view of a third embodiment of the delivery device of the invention in prepared form.
  • FIG. 1A depicts, in a cross-sectional view, one embodiment of the delivery device according to the invention.
  • the device is in prepared form prior to placement in a fluid.
  • Dispensing device 1 is shown in FIG. 1A to comprise a hollow active agent formulation chamber 10 with a first end 16 and a second end 18 . Contained within chamber 10 are active agent formulation 12 and fluid passing active agent formulation retainer 14 .
  • the fluid passing active agent formulation retainer 14 comprises a restriction 24 and a one-way plug 28 .
  • the diameter of opening 20 is smaller then the plug 28 .
  • the restriction is made by crimping the end 16 of chamber 10 .
  • Second end 18 of chamber 10 has an active agent formulation retainer 26 for preventing release of plug 28 .
  • FIG. 1A depicts, in a cross-sectional view, one embodiment of the delivery device according to the invention.
  • the device is in prepared form prior to placement in a fluid.
  • Dispensing device 1 is shown in FIG. 1A to comprise a hollow active agent formulation
  • the retainer 26 is prepared by crimping the end 18 of chamber 10 .
  • Active agent formulation 12 which can be particles of drug, coated drug particles, or "tiny time pills", either alone or with additional carriers, is then placed in the chamber 10 .
  • End-cap 34 is placed over the second end 18 of the chamber 10 prior to use to prevent release of the active agent formulation 12 .
  • FIG. 1B is an enlarged view of plug 28 , showing that, in prepared form, plug 28 essentially seals the first end 16 of the chamber 10 , thereby preventing loss of active agent formulation 12 from the first end 16 .
  • FIG. 2A shows the delivery device 1 in operation after having been placed in fluid 30 .
  • the first end 16 of the delivery device 1 is placed in the fluid 30 and the second end 18 of the device is placed in the patient's mouth.
  • the patient sips on the second end 18 of the device and an admixture of fluid 30 and active agent formulation 12 is delivered through opening 22 and into the patient's mouth.
  • the plug 28 serves as a one-way valve. When suction is applied through the tubular member 10 , the plug 28 is deformed, thereby permitting fluid to flow around the plug 28 as shown by arrows 32 . When suction is removed, the plug 28 relaxes and automatically seals the chamber 10 (see FIG. 3B).
  • the plug 28 which has a density of less than 1, moves up the elongated tubular member, thereby aiding in delivery of the active agent formulation 12 .
  • the position of plug 28 in chamber 10 serves as an indicator of approximately how much of the active agent formulation 12 has actually been delivered.
  • FIG. 3A shows delivery device 1 after delivery of the active agent formulation has essentially been completed.
  • the plug 28 is seated adjacent the opening 22 but it does not leave the chamber 10 since the diameter of the opening is less than the diameter of the plug 28 (see FIG 3B).
  • the position of plug 28 adjacent the opening 22 serves as an indication that the entire active agent formulation 12 has been delivered.
  • FIG.4 A is a cross-sectional view of another embodiment of the device of the invention in prepared form prior to placement in a fluid.
  • the active agent formulation chamber 60 of delivery device 62 is of essentially uniform diameter over its entire length.
  • the fluid passing active agent formulation retainer 80 comprises a plug 28 and an end cap 64 .
  • End cap 66 is positioned over the second end 72 end of the chamber 60 and forms the active agent formulation retainer 82 .
  • End cap 64 positioned over the first end 68 of the chamber 60 , is designed to allow free passage of fluid but to prevent displacement of the one-way plug 28 from the first end 68 of chamber 60 . As shown in FIG.
  • the end cap 64 may have a cross-shaped inner member 70 , however, any conveniently shaped inner member is contemplated that will allow for passage of fluid but will not permit displacement of the one-way plug 28 .
  • End cap 66 placed over the second end 72 of the chamber 60 , is designed to allow free passage of liquid when suction is applied by the patient, but to provide a means for closing the end of the device prior to use. Accordingly, rotary valve 74 is placed over end cap 66 .
  • FIG. 4C The top view of both end cap 66 and rotary valve 74 are shown in FIG. 4C. This configuration allows for free passage of fluid when the open sections 76 are aligned with each other and for prevention of fluid flow when the open sections 76 are aligned with closed sections 78 .
  • FIG. 4D is a top view of the device of FIG. 4A when the open sections 76 of the valve 74 are aligned with the closed sections 78 of the end cap 66 .
  • FIG. 5 is a cross-sectional view of an embodiment that is similar to that shown in FIG. 1 but the second end of 120 of the active agent formulation chamber 122 is not crimped but rather has an active agent formulation retainer 124 , in this case a tab that can be pulled out, leaving behind a protrusion 126 that will prevent release of the plug 28 following delivery of the active agent formulation 12 .
  • the active agent itself may be in liquid, solid, or semisolid form.
  • the active agent formulation that contains the active agent may contain additional material such as binders, coating materials, or stabilizers such that the formulation is formed into one or more discrete units.
  • the discrete units may be designed in a multitude of ways to provide a specific drug delivery profile.
  • One embodiment comprises a formulation that is in particulate form. These particulates are generally between about 50 and 2000 ⁇ m in diameter, usually between about 100-500 ⁇ m in diameter. Where the particulate has an unpleasant taste, the particulate may be taste masked by methods that are well known in the art.
  • the particulates may be designed to provide immediate delivery of the active agent, they may be coated to provide for prolonged release or delayed pulse release of the active agent, or they may be designed to provide for a combination of immediate, pulsed and/or prolonged delivery of active agent.
  • the particulates may be coated with an enteric coating to provide for targetted release of the active agent.
  • active agent formulations that contain more than one active agent.
  • the active agent may be in liquid form and may be contained within a soft gelatin capsule or within a solid oral dosage form.
  • dosage forms may include, matrix or other types of tablets, pellets and elongated tablets where the height to diameter ratio exceeds one, capsules, elementary osmotic pumps, such as those described in US Patent No. 3,845,770, mini osmotic pumps such as those described in US Patent Nos. 3,995,631, 4,034,756, and 4,111,202, and multichamber osmotic systems referred to as push-pull and push-melt osmotic pumps, such as those described in US Patent Nos. 4,320,759, 4,327,725, 4,449,983, and 4,765,989 all of which are incorporated herein by reference.
  • active agent refers to an agent, drug, compound, composition of matter or mixture thereof which provides some pharmacologic, often beneficial, effect. This includes foods, food supplements, nutrients, drugs, vitamins, and other beneficial agents. As used herein, the terms further include any physiologically or pharmacologically active substance that produces a localized or systemic effect in a patient.
  • the active drug that can be delivered includes antibiotics, antiviral agents, anepileptics, analgesics, anti-inflammatory agents and bronchodilators, and may be inorganic and organic compounds, including, without limitation, drugs which act on the peripheral nerves, adrenergic receptors, cholinergic receptors, the skeletal muscles, the cardiovascular system, smooth muscles, the blood circulatory system, synoptic sites, neuroeffector junctional sites, endocrine and hormone systems, the immunological system, the reproductive system, the skeletal system, autacoid systems, the alimentary and excretory systems, the histamine system and the central nervous system.
  • antibiotics antibiotics, antiviral agents, anepileptics, analgesics, anti-inflammatory agents and bronchodilators, and may be inorganic and organic compounds, including, without limitation, drugs which act on the peripheral nerves, adrenergic receptors, cholinergic receptors, the skeletal muscles, the cardiovascular system, smooth muscles, the blood circulatory
  • Suitable agents may be selected from, for example, polysaccharides, steroids, hypnotics and sedatives, psychic energizers, tranquilizers, anticonvulsants, muscle relaxants, antiparkinson agents, analgesics, anti-inflammatories, muscle contractants, antimicrobials, antimalarials, hormonal agents including contraceptives, sympathomimetics, polypeptides and proteins capable of eliciting physiological effects, diuretics, lipid regulating agents, antiandrogenic agents, antiparasitics, neoplastics, antineoplastics, hypoglycemics, nutritional agents and supplements, growth supplements, fats, ophthalmics, antienteritis agents, electrolytes and diagnostic agents.
  • active agents useful in this invention include prochlorperazine edisylate, ferrous sulfate, aminocaproic acid, mecamylamine hydrochloride, procainamide hydrochloride, amphetamine sulfate, methamphetamine hydrochloride, benzphetamine hydrochloride, isoproterenol sulfate, phenmetrazine hydrochloride, bethanechol chloride, methacholine chloride, pilocarpine hydrochloride, atropine sulfate, scopolamine bromide, isopropamide iodide, tridihexethyl chloride, phenformin hydrochloride, methylphenidate hydrochloride, theophylline cholinate, cephalexin hydrochloride, diphenidol, meclizine hydrochloride, prochlorperazine maleate, phenoxybenzamine, thiethylperazine maleate
  • proteins and peptides which include, but are not limited to, insulin, colchicine, glucagon, thyroid stimulating hormone, parathyroid and pituitary hormones, calcitonin, renin, prolactin, corticotrophin, thyrotropic hormone, follicle stimulating hormone, chorionic gonadotropin, gonadotropin releasing hormone, bovine somatotropin, porcine somatropin, oxytocin, vasopressin, prolactin, somatostatin, lypressin, pancreozymin and luteinizing hormone.
  • the agents can be in various forms, such as soluble and insoluble charged or uncharged molecules, components of molecular complexes or nonirritating, pharmacologically acceptable salts.
  • the amount of active agent employed in the delivery device will be that amount necessary to deliver a therapeutically effective amount of the agent to achieve the desired result. In practice, this will vary widely depending upon the particular agent, the severity of the condition, and the desired therapeutic effect. However, the device is generally useful for active agents that must be delivered in fairly large doses of from about 100 mg to 5000 mg, usually in the range of from about 250 mg to about 2500 mg. However, since the devices may also be useful in pediatric patients, doses in the ranges of 25 to 250 mg are also contemplated herein.
  • Representative materials for forming devices including the active agent formulation chamber, the elongated tubular member, the end caps and tabs include, without limitation, paper, plastic such as propylene/styrene copolymers, polyproylene, high density polyethylene, low density polyethylene and the like.
  • the devices usually have an inner diameter of between about 3 and 8 mm and a wall thickness of between about 0.1 and 0.4 mm.
  • the devices are between about 10 and 30 cm in length.
  • the fluid passing active agent formulation retainer permits the free flow of liquid medium but prohibits passage of the active agent formulation from the device prior to delivery.
  • the retainer comprises a one-way plug or valve
  • the plug or valve will seal the straw at atmospheric pressure. When suction is applied, fluid will be draw around the plug and into the active agent formulation chamber. Further, the plug has a density of less than one so that it will ascend to the top as the active agent formulation is delivered into the oral cavity. When suction is no longer applied, the plug will remain in the highest position it reached during sipping.
  • the plug may be prepared from closed cell polyethylene foam such as EthaFoam®. Other forms of one way plugs can be a balloon of elastomeric material, a one-way mechanical ball valve and the like.
  • the fluid that is used for suspending the active agent formulation by sipping through the active agent formulation chamber is preferably any good-tasting liquid including but not limited to water, juice, milk, soda, coffee, tea etc. Care must be taken to ensure compatibility of the fluid with the active agent formulation.
  • a delivery device was prepared as follows. Jumbo size straws with an inside diameter of 0.21 inches and a length of 8 inches were heat sealed at one end. The seal was partially cut off so that the "one-way" plug could not escape. The partially sealed end was enclosed by half of a size 1 hard gelatin capsule. 600 mg of membrane coated potassium chloride microparticles with a particle size of about 0.5 mm from a Micro-K Extencap® (A.H. Robins) were placed inside the open end of the straw. A "one-way" plug made of closed cell polyethylene foam, Microfoam® (DuPont) was trimmed to snugly fit inside the straw. The plug was then placed inside the straw, on top of the Micro-K particles.
  • the plug end of the straw was placed into a glass of water and the protective gelatin capsule on the top of the straw was removed.
  • the 600 mg of Micro-K particles were sucked into the mouth and easily swallowed.
  • the device was prepared according to Example 1, but instead of Micro-K, the contents of a Contact® 12 hour capsule (SmithKline Beechem), an over the counter continuous action nasal decongestant/antihistamine containing 25 mg phenylpropanolamine and 12 mg chlorpheniramine maleate were inserted into the straw.
  • the microparticulates were in the range of between about 0.5 and 1.0 mm. The particulates were sucked into the mouth as described in Example 1.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Feeding, Discharge, Calcimining, Fusing, And Gas-Generation Devices (AREA)
  • Vending Machines For Individual Products (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (14)

  1. Système distributeur de principe actif par voie orale, pour distribuer des unités discrètes d'une formulation d'un principe actif en mélange avec un fluide, ledit système comprenant :
    une chambre creuse (10,60,122) pour la formulation du principe actif, ladite chambre ayant une première extrémité (16, 68) et une deuxième extrémité (18,72,120) et contenant une formulation de principe actif (12) sous forme d'unités discrètes, lesdites extrémités étant adaptées de façon à permettre le passage du fluide pendant la distribution de la formulation du principe actif ; et un dispositif de retenue (14, 28, 80) pour la formulation du principe actif, permettant le passage du fluide, se trouvant dans ladite chambre (10) contenant la formulation du principe actif, pour empêcher que les unités discrètes ne s'échappent par la première extrémité de la chambre, tout en permettant au fluide de pénétrer dans la chambre ;
    ledit système distributeur étant caractérisé en ce que ledit dispositif de retenue (28) peut se déplacer vers la deuxième extrémité (18,72,120) avec le fluide pénétrant dans le système.
  2. Système distributeur selon la revendication 1, qui comprend en outre un dispositif (26, 82, 124) de retenue de la formulation du principe actif dans la deuxième extrémité (18,72,120) de la chambre (10,60,122) contenant la formulation du principe actif, pour empêcher que ladite formulation de principe actif ne s'échappe par la deuxième extrémité avant utilisation.
  3. Système distributeur selon la revendication 1, dans lequel les unités discrètes sont choisies dans l'ensemble comprenant les particules, les formes posologiques orales et leurs combinaisons.
  4. Système distributeur selon la revendication 3, dans lequel lesdites unités discrètes assurent une libération prolongée du principe actif dans ladite formulation.
  5. Système distributeur selon la revendication 3, dans lequel lesdites unités discrètes assurent une libération immédiate du principe actif dans ladite formulation.
  6. Système distributeur selon la revendication 3, dans lequel lesdites unités discrètes assurent une libération pulsée retardée dudit principe actif dans ladite formulation.
  7. Système distributeur selon la revendication 3, dans lequel lesdites unités discrètes comprennent des formes posologiques orales qui sont constituées d'une couche osmotique et d'une couche d'un principe actif.
  8. Système distributeur selon la revendication 1, dans lequel ledit dispositif de retenue de la formulation du principe actif comprend un bouchon à une voie (28).
  9. Système distributeur selon la revendication 8, dans lequel la position du bouchon (28) est un indicateur de l'importance de la libération du principe actif.
  10. Système distributeur selon la revendication 1, qui comprend en outre un capuchon en bout (64), qui entoure d'une manière concentrique la première extrémité (16) de la chambre.
  11. Système distributeur selon la revendication 2, dans lequel ledit dispositif (82) de retenue de la formulation du principe actif dans la deuxième extrémité (18) de la chambre comprend une valve rotative (74).
  12. Système distributeur selon la revendication 2, dans lequel ledit dispositif (124) de retenue de la formulation du principe actif dans la deuxième extrémité (18) de la chambre comprend un rétrécissement (126) dans la deuxième extrémité de la deuxième extrémité de la chambre (18).
  13. Système distributeur selon la revendication 2, dans lequel ledit dispositif (82) de retenue de la formulation du principe actif dans la deuxième extrémité (18) de la chambre comprend un capuchon en bout (66) amovible.
  14. Système distributeur selon la revendication 1, dans lequel ladite formulation de principe actif comprend un principe actif choisi dans l'ensemble comprenant les antibiotiques, les agents antiviraux, les antiépileptiques, les analgésiques, les agents anti-inflammatoires et les broncho-dilatateurs.
EP96924555A 1995-07-21 1996-07-17 Systeme pour administration d'unites discretes par voie orale Expired - Lifetime EP0840591B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP00200063A EP0988850B1 (fr) 1995-07-21 1996-07-17 Un dispositif d'administration d'agent oralement actif

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US131995P 1995-07-21 1995-07-21
US131995 1995-07-21
US58254496A 1996-01-03 1996-01-03
US582544 1996-01-03
PCT/US1996/011812 WO1997003634A1 (fr) 1995-07-21 1996-07-17 Administration d'unites discretes par voie orale

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP00200063A Division EP0988850B1 (fr) 1995-07-21 1996-07-17 Un dispositif d'administration d'agent oralement actif

Publications (2)

Publication Number Publication Date
EP0840591A1 EP0840591A1 (fr) 1998-05-13
EP0840591B1 true EP0840591B1 (fr) 2001-03-14

Family

ID=26668856

Family Applications (2)

Application Number Title Priority Date Filing Date
EP00200063A Expired - Lifetime EP0988850B1 (fr) 1995-07-21 1996-07-17 Un dispositif d'administration d'agent oralement actif
EP96924555A Expired - Lifetime EP0840591B1 (fr) 1995-07-21 1996-07-17 Systeme pour administration d'unites discretes par voie orale

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP00200063A Expired - Lifetime EP0988850B1 (fr) 1995-07-21 1996-07-17 Un dispositif d'administration d'agent oralement actif

Country Status (17)

Country Link
EP (2) EP0988850B1 (fr)
JP (1) JP3818664B2 (fr)
KR (1) KR100449538B1 (fr)
CN (1) CN1113640C (fr)
AT (1) ATE199638T1 (fr)
AU (1) AU713120B2 (fr)
BR (1) BR9609696A (fr)
CA (1) CA2226267C (fr)
DE (1) DE69612098T2 (fr)
DK (2) DK0988850T3 (fr)
ES (2) ES2154829T3 (fr)
GR (1) GR3035850T3 (fr)
HK (1) HK1015671A1 (fr)
NZ (2) NZ313010A (fr)
PT (1) PT840591E (fr)
TW (1) TW347339B (fr)
WO (1) WO1997003634A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008122438A2 (fr) * 2007-04-10 2008-10-16 Sandoz Ag Dispositif d'application orale de substance

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030087005A1 (en) 1996-10-10 2003-05-08 Peter Baron Drink flavouring straw
AU721882B2 (en) 1996-10-10 2000-07-13 Club Investments (Aust) Pty Ltd Method and apparatus for producing a flavoured beverage
AUPS270602A0 (en) 2002-05-31 2002-06-20 Baron, Peter Drink flavouring straw
AU729905B2 (en) 1996-10-18 2001-02-15 Alza Corporation Multiple flow path device for oral delivery of discrete units
CA2268887C (fr) * 1996-10-18 2003-11-25 Alza Corporation Systeme de fermeture pour dispositif d'administration d'agents actifs
US6024721A (en) * 1996-10-18 2000-02-15 Alza Corporation Mixing system for an active agent delivery device
WO1998034598A2 (fr) * 1997-02-07 1998-08-13 Gist-Brocades B.V. Formulations homogenes sous forme de granules destinees a la technologie d'aspiration des doses
EP0966206B1 (fr) 1997-03-14 2005-05-25 Unilever N.V. Produit alimentaire congele contenant des peptides antigel
US5985324A (en) 1997-05-16 1999-11-16 Alza Corporation Flow controller configurations for an active agent delivery device
US8052982B2 (en) 1998-07-20 2011-11-08 Peptech Animal Health Pty Limited Bioimplant formulation comprising lecithin and stearin
JPWO2004100859A1 (ja) * 2003-05-14 2006-07-13 株式会社クレハ 経口摂取用固形成形物の嚥下用収容体、その収容体用の容器、及び嚥下方法
DE10342513A1 (de) * 2003-09-12 2005-05-12 Gruenenthal Gmbh Darreichungsform zur oralen Verabreichung von Wirkstoffen, Vitaminen und/oder Nährstoffen, Kit und Verwendung
DE10342514A1 (de) * 2003-09-12 2005-04-07 Grünenthal GmbH Darreichungsform zur oralen Verabreichung von Wirkstoffen, Vitaminen und/oder Nährstoffen, Kit und Verwendung
US20060034886A1 (en) * 2004-07-23 2006-02-16 Ward Bennett C Bonded fiber structures for use in controlling fluid flow
DE102005004256A1 (de) * 2005-01-28 2006-08-10 Grünenthal GmbH Trinkhalm mit einer Versteifung
DE102005004257A1 (de) * 2005-01-28 2006-08-24 Grünenthal GmbH Verfahren zur Herstellung eines Trinkhalms mit Controller
US20080312587A1 (en) * 2005-06-10 2008-12-18 Gruenethal Gmbh System for the Oral Administration of Solids to Persons Suffering from Dementia
DE102005029289A1 (de) * 2005-06-22 2006-12-28 Grünenthal GmbH Kappe für einen Trinkhalm mit einem zylindrischen Innendorn
AR060029A1 (es) 2006-03-02 2008-05-21 Unistraw Patent Holdings Ltd Pajilla para beber adaptada para acondicionar progresivamente un ingrediente activo y metodo de fabricar dicha pajilla
WO2008092200A1 (fr) 2007-01-31 2008-08-07 Sands Innovations Pty Ltd Ustensile de distribution et procédé de fabrication associé
WO2010029095A2 (fr) * 2008-09-10 2010-03-18 Sandoz Ag Capsule avec élément de bouchage soluble
EP2163242A1 (fr) 2008-09-10 2010-03-17 Sandoz AG Capsule dotée d'un élément de blocage soluble
CN101537919B (zh) * 2009-04-22 2014-02-19 广东润科生物工程有限公司 一种用于饮用固体物料的器具
DE202011104802U1 (de) * 2011-08-20 2012-01-26 Christian Kober Strohhalm zur Messung schädlicher Stoffe bzw. von Partydrogen in Getränken
US9017749B2 (en) 2011-12-21 2015-04-28 Babatope Sewande Ayeni Flavored straw with a flavor delivery system
DE202012005997U1 (de) 2012-06-20 2012-07-18 Claus Linder Gefäß für Getränke und Flüssigkeiten jeglicher Art zur Messung schädlicher Stoffe bzw. Rauschgift und Partydrogen in Getränken
US9005108B2 (en) * 2012-09-27 2015-04-14 Palo Alto Research Center Incorporated Multiple reservoir drug delivery device and methods
GB201401516D0 (en) * 2014-01-29 2014-03-12 Unistraw Holdings Pte Ltd Drinking straw with piercing end
USD767931S1 (en) 2013-09-12 2016-10-04 Unistraw Holdings Pte. Ltd. Beverage straw end with a beak
CN105030004B (zh) * 2015-05-06 2017-01-04 曹杨 一种储物式吸管
WO2018156853A1 (fr) 2017-02-24 2018-08-30 Bolton Medical, Inc. Système de mise en place pour la constriction radiale d'une greffe de stent et procédé d'utilisation
US20220257471A1 (en) * 2019-09-30 2022-08-18 Shanghai Wd Pharmaceutical Co., Ltd Drug accommodating device of solid oral formulation, and oral administration and delivery apparatus comprising same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2436505A (en) * 1945-08-24 1948-02-24 Rall John H Du Pill douser
US2867536A (en) * 1954-05-07 1959-01-06 Mead Bruce Ronald Flavor-containing drinking straw
DE1906964A1 (de) * 1969-02-07 1970-08-20 Ernst Ruediger Trinkhalm
US3610483A (en) * 1969-12-01 1971-10-05 Ralph Visconti Dispenser with liquid-impervious vent
US4792333A (en) * 1986-11-04 1988-12-20 Strawdose, Inc. Unit dose drug package and administering device
US4981468A (en) * 1989-02-17 1991-01-01 Eli Lilly And Company Delivery device for orally administered therapeutic agents

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008122438A2 (fr) * 2007-04-10 2008-10-16 Sandoz Ag Dispositif d'application orale de substance
WO2008122438A3 (fr) * 2007-04-10 2008-12-04 Sandoz Ag Dispositif d'application orale de substance

Also Published As

Publication number Publication date
NZ333997A (en) 1999-03-29
GR3035850T3 (en) 2001-08-31
AU6498096A (en) 1997-02-18
HK1015671A1 (en) 1999-10-22
EP0840591A1 (fr) 1998-05-13
CA2226267A1 (fr) 1997-02-06
DK0988850T3 (da) 2005-01-24
NZ313010A (en) 1999-03-29
TW347339B (en) 1998-12-11
KR19990028664A (ko) 1999-04-15
JP3818664B2 (ja) 2006-09-06
EP0988850A2 (fr) 2000-03-29
EP0988850A3 (fr) 2000-05-17
DE69612098D1 (de) 2001-04-19
ATE199638T1 (de) 2001-03-15
DK0840591T3 (da) 2001-04-17
BR9609696A (pt) 1999-03-23
KR100449538B1 (ko) 2004-12-17
JPH11510066A (ja) 1999-09-07
EP0988850B1 (fr) 2004-09-22
WO1997003634A1 (fr) 1997-02-06
CN1113640C (zh) 2003-07-09
CA2226267C (fr) 2008-01-22
CN1191476A (zh) 1998-08-26
PT840591E (pt) 2001-06-29
ES2228398T3 (es) 2005-04-16
AU713120B2 (en) 1999-11-25
DE69612098T2 (de) 2001-06-21
ES2154829T3 (es) 2001-04-16

Similar Documents

Publication Publication Date Title
EP0840591B1 (fr) Systeme pour administration d'unites discretes par voie orale
US5780058A (en) Oral delivery of discrete units
AU733022B2 (en) Flow controller configurations for an active agent delivery device
CA2268887C (fr) Systeme de fermeture pour dispositif d'administration d'agents actifs
US6024721A (en) Mixing system for an active agent delivery device
CA2268637C (fr) Dispositif a plusieurs voies d'ecoulement pour administrer des unites discretes par voie orale
AU742022B2 (en) Oral delivery of discrete units
IL119787A (en) Oral delivery system of individual units
MXPA98000596A (en) Oral asset system of discrete agent act units

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980126

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 19990505

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

RTI1 Title (correction)

Free format text: ORAL DELIVERY SYSTEM FOR DELIVERY OF DISCRETE UNITS

RTI1 Title (correction)

Free format text: ORAL DELIVERY SYSTEM FOR DELIVERY OF DISCRETE UNITS

RTI1 Title (correction)

Free format text: ORAL DELIVERY SYSTEM FOR DELIVERY OF DISCRETE UNITS

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

REF Corresponds to:

Ref document number: 199638

Country of ref document: AT

Date of ref document: 20010315

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

ITF It: translation for a ep patent filed

Owner name: JACOBACCI & PERANI S.P.A.

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM & CO. PATENTANWAELTE

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2154829

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69612098

Country of ref document: DE

Date of ref document: 20010419

ET Fr: translation filed
REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20010319

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20060719

Year of fee payment: 11

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: ALZA CORPORATION

Free format text: ALZA CORPORATION#950 PAGE MILL ROAD P.O. BOX 10950#PALO ALTO CALIFORNIA 94303-0802 (US) -TRANSFER TO- ALZA CORPORATION#950 PAGE MILL ROAD P.O. BOX 10950#PALO ALTO CALIFORNIA 94303-0802 (US)

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20080331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070731

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 69612098

Country of ref document: DE

Representative=s name: SCHAUMBURG UND PARTNER PATENTANWAELTE MBB, DE

Ref country code: DE

Ref legal event code: R082

Ref document number: 69612098

Country of ref document: DE

Representative=s name: SCHAUMBURG & PARTNER PATENTANWAELTE GBR, DE

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20150611

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20150615

Year of fee payment: 20

Ref country code: LU

Payment date: 20150715

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20150709

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20150715

Year of fee payment: 20

Ref country code: PT

Payment date: 20150716

Year of fee payment: 20

Ref country code: IE

Payment date: 20150709

Year of fee payment: 20

Ref country code: DE

Payment date: 20150714

Year of fee payment: 20

Ref country code: CH

Payment date: 20150713

Year of fee payment: 20

Ref country code: FI

Payment date: 20150709

Year of fee payment: 20

Ref country code: DK

Payment date: 20150713

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20150625

Year of fee payment: 20

Ref country code: BE

Payment date: 20150713

Year of fee payment: 20

Ref country code: SE

Payment date: 20150713

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20150727

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69612098

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MK

Effective date: 20160716

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

Effective date: 20160717

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20160716

REG Reference to a national code

Ref country code: IE

Ref legal event code: MK9A

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 199638

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160717

REG Reference to a national code

Ref country code: GR

Ref legal event code: MA

Ref document number: 20010400700

Country of ref document: GR

Effective date: 20160718

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20161026

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20160717

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20160716

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20160726

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20160718